Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
671
datasets available to search
ShareScore release 0.9.0
Dataset results
671 results for “Dilatancy”
Data from: High reproducibility of adenosine stress cardiac magnetic resonance myocardial perfusion imaging in patients with nonischemic dilated cardiomyopathy
Objective: To evaluate the reproducibility of first-pass contrast-enhanced cardiac MR (CMR) myocardial perfusion imaging in patients with non-ischaemic dilated cardiomyopathy (NIDCM). Design: Prospective observational study. Setting: Single centre, tertiary care hospital. Participants: 6 outpatient participants with NIDCM. Outcome: Reproducibility of semiquantitative myocardial perfusion analysis by CMR. Method: 6 patients with NIDCM were studied twice using first-pass of contrast transit through the left ventricular (LV) myocardium with a saturation-recovery gradient echo sequence at rest and during adenosine-induced hyperaemia. The anterior wall was divided into endocardial (Endo) and epicardial (Epi) segments. The Myocardial Perfusion Index (MPI) was calculated as the myocardial signal augmentation rate normalised to the LV cavity rate. The Myocardial Perfusion Reserve Index (MPRI) was calculated as hyperaemic/resting MPI. Results: Between study 1 and 2, median MPI was similar for resting Endo (0.076 vs 0.077), hyperaemic Endo (0.143 vs 0.143), resting Epi (0.073 vs 0.074), and hyperaemic Epi (0.135 vs 0.134). Median MPRI was similar for Endo (1.84 vs 1.87) and Epi (1.90 vs 2.00). Combining Endo and Epi MPI (N=12), there was excellent agreement between Study 1 and 2 for resting MPI (r=0.998, intraclass correlation coefficient (ICC) 0.998, coefficients of variation (CoV) 1.4%), hyperaemic MPI (r=0.979, ICC 0.963, CoV 3.3%) and MPRI (r=0.989, ICC 0.94, CoV 3.8%). Conclusions: Resting and hyperaemic myocardial perfusion using a normalised upslope analysis during adenosine CMR is a highly reproducible technique in patients with NIDCM. Trial registration number: Clinical Trials.Gov ID NCT00574119.
Data from: Pupil dilation as an index of preferred mutual gaze duration
Most animals look at each other to signal threat or interest. In humans, this social interaction is usually punctuated with brief periods of mutual eye contact. Deviations from this pattern of gazing behaviour generally make us feel uncomfortable and are a defining characteristic of clinical conditions such as autism or schizophrenia, yet it is unclear what constitutes normal eye contact. Here, we measured, across a wide range of ages, cultures and personality types, the period of direct gaze that feels comfortable and examined whether autonomic factors linked to arousal were indicative of people's preferred amount of eye contact. Surprisingly, we find that preferred period of gaze duration is not dependent on fundamental characteristics such as gender, personality traits or attractiveness. However, we do find that subtle pupillary changes, indicative of physiological arousal, correlate with the amount of eye contact people find comfortable. Specifically, people preferring longer durations of eye contact display faster increases in pupil size when viewing another person than those preferring shorter durations. These results reveal that a person's preferred duration of eye contact is signalled by physiological indices (pupil dilation) beyond volitional control that may play a modulatory role in gaze behaviour.
Data from: One-shot dilation versus serial dilation technique for access in percutaneous nephrolithotomy: a systematic review and meta-analysis
Objective: The purpose of this study was to systematically review the outcomes of the use of one-shot dilation (OSD) and serial tract dilation for percutaneous nephrolithotomy (PCNL). Methods: A systematic review and meta-analysis was conducted. The randomized controlled trials (RCTs) included in the study were identified from EMBASE, MEDLINE, and the Cochrane Central Register of Controlled Trials. The last search was performed on April 30, 2018. Summary effects were calculated as risk ratios (RRs) with 95% confidence intervals (CIs) or mean differences (MDs) with 95% CIs. The endpoints included access time, fluoroscopy time, successful dilation rate, stone-free rate, postoperative decrease in hemoglobin levels, transfusion rate, complication rate, and length of postoperative hospital stay. Results: A total of 7 RCTs were included in the study, with clinical data reported for 697 patients. The overall access time was approximately 110 seconds shorter in the OSD group than in the serial dilation group (MD, -110.14; 95% CI, -161.99 to -58.30; P<0.0001). The fluoroscopy time was shorter with OSD in all RCTs. In addition, the decrease in postoperative hemoglobin levels was approximately 0.23 g/dl less in patients in the OSD group than in those in the serial dilation group (MD, -0.23; 95% CI, -0.39 to -0.07; P=0.004). No relationship was found between the successful dilation rate, stone-free rate, transfusion rate, or complication rate and the method of tract dilation. Conclusion: OSD is a safe and efficacious tract dilation technique that can reduce the access time, fluoroscopy time, and postoperative decrease in hemoglobin level. No difference was found in the successful dilation rate, stone-free rate, transfusion rate, or rate of complications between the OSD and serial dilation groups. The difference in the length of postoperative hospital stay was uncertain. OSD may be a better method of tract creation for PCNL.
Supplemental data: The association of dilated perivascular spaces with cognitive decline and incident dementia
<p><span><b>Objective:</b></span></p> <p><span>To determine if severe perivascular space (PVS) dilation is associated with longitudinal cognitive decline and incident dementia over four and eight years respectively, we analyzed data from a prospective cohort study.</span></p> <p><span><b>Methods: </b></span></p> <p>414 community dwelling older adults aged 72-92 were assessed at baseline and biennially for up to eight years, with cognitive assessments, consensus dementia diagnoses and 3T MRI imaging. The numbers of PVS in two representative slices in the basal ganglia (BG) and centrum semiovale (CSO) were counted and severe PVS pathology defined as the top quartile. The effects of severe PVS pathology in i) either region; ii) both regions; and those with iii) severe BG PVS and iv) severe CSO PVS were examined. White matter hyperintensity volume, cerebral microbleed number and lacune number were calculated.</p> <p><span><b>Results:</b></span></p> <p>Participants with severe PVS pathology in both regions or in the CSO alone had greater decline in global cognition over four years, even after adjustment for the presence of other small vessel disease neuroimaging markers. The presence of severe PVS pathology in both regions was an independent predictor of dementia across eight years (OR 2.91, 95%CI 1.43–5.95, p= 0.003). Further, the presence of severe PVS pathology in all groups examined was associated with greater dementia risk at either year four or six.</p> <p><span><b>Conclusions: </b></span></p> <p>Severe PVS pathology is a marker for increased risk of cognitive decline and dementia, independent of other small vessel disease markers. The differential cognitive associations for BG and CSO PVS may represent differences in their underlying pathology.</p>
Searching for the relationship between the presence, extent, location and 12-month dynamics of cardiac fibrosis and the genetic profile in patients with dilated cardiomyopathy - a pilot study
Open the record for dataset details and reuse information.
Effects of inhaled double-branch dilator Umeclidinium/Vilanterol on pulmonary function and inflammatory factors in patients with stable chronic obstructive pulmonary disease
Open the record for dataset details and reuse information.
Raw data -- Analysis of variance for fixation duration ,number of fixations ,pupil dilation ,saccadic amplitude of participants at different levels.
<p>原始数据 -- 分析不同水平参与者注视持续时间、注视次数、瞳孔扩张、扫视幅度的方差。</p>
A Study to EXhibit Percutaneous Coronary Artery Dilatation With Non-Slip Element Balloon
ClinicalTrials.gov study NCT04985773. IPD Sharing: NO. Countries: 1. Publications: 0.
Endoscopic Balloon Dilation vs Surgery to Treat Short Strictures in Fibrostenosing Crohns Disease: An RCT
ClinicalTrials.gov study NCT03735355. IPD Sharing: NO. Countries: 0. Publications: 1.
Efficacy of Brooke Bond Black Tea Extract on Flow Mediated Dilation in Indian Males
ClinicalTrials.gov study NCT01561300. IPD Sharing: NO. Countries: 1. Publications: 0.
Dilator Muscle Activity in Health and Sleep Apnea
ClinicalTrials.gov study NCT04254341. IPD Sharing: Not stated. Countries: 0. Publications: 2.
Zinc Deficiency in Dilated Cardiomyopathy
ClinicalTrials.gov study NCT04860921. IPD Sharing: UNDECIDED. Countries: 0. Publications: 1.
Safety and Efficacy of Phenylephrine 2.5%-Tropicamide 1% Microdose Ophthalmic Solution for Pupil Dilation
ClinicalTrials.gov study NCT03751098. IPD Sharing: NO. Countries: 1. Publications: 0.
Balloon Sinus Dilation In Office or OR
ClinicalTrials.gov study NCT00939393. IPD Sharing: NO. Countries: 1. Publications: 0.
Coenzyme Q10 Supplementation in Children With Idiopathic Dilated Cardiomyopathy
ClinicalTrials.gov study NCT02115581. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Study of the Efficiency of Esophageal Dilation on Patient With Eosinophilic Esophagitis
ClinicalTrials.gov study NCT00880906. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Effect of Ultimaster Stents Treated to the Most Dilated Coronary Vessels
ClinicalTrials.gov study NCT04931784. IPD Sharing: NO. Countries: 0. Publications: 1.
Value of Mifepristone in Cervical Preparation Prior to Dilation and Evacuation 19-24 Weeks
ClinicalTrials.gov study NCT01615731. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Drug-eluting PTA Balloon Dilatation Catheter in the Treatment of Peripheral Artery Stenosis or Occlusion
ClinicalTrials.gov study NCT03844724. IPD Sharing: Not stated. Countries: 0. Publications: 1.
Safety and Efficacy of Phenylephrine 2.5%-Tropicamide 1% Microdose Ophthalmic Solution for Pupil Dilation
ClinicalTrials.gov study NCT03751631. IPD Sharing: NO. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.